SB 249 creates a new statutory framework in Delaware for substance use harm reduction programs and updates the state’s drug paraphernalia laws to better align with that framework. The bill defines key terms such as harm reduction, supplies, syringe, needle, opioid antagonist, and sexually transmitted disease barrier, and authorizes the Division of Substance Abuse and Mental Health to regulate licensing and operation of harm reduction programs through evidence-based rules. It also allows programs to operate mobile services and peer-delivered services.
The bill requires harm reduction programs to provide sterile supplies, drug-testing strips, opioid antagonists such as naloxone, and sexually transmitted disease barriers, along with services including safe disposal, HIV and hepatitis screening, wound care, overdose education, and referrals for primary care, behavioral health care, vaccinations, housing, transportation, and public benefits. It also protects participant anonymity and confidentiality, limits mandatory data collection, and provides immunity from criminal, civil, and licensing liability for people acting in good faith under the chapter, absent gross negligence or similar misconduct.
In addition to creating the harm reduction chapter, SB 249 revises Title 16’s drug paraphernalia definitions and offenses. It narrows and modernizes the definition of drug paraphernalia, removes certain outdated references, and repeals several provisions in Title 29. The bill also changes the treatment of paraphernalia possession so that possession for personal use of marijuana is subject to a civil penalty rather than criminal punishment, while retaining criminal penalties for manufacture, sale, delivery, and delivery to minors, and preserving law enforcement’s ability to use paraphernalia as evidence in controlled substance cases.
The overall sentiment reflected in the bill text is strongly supportive of public-health-oriented harm reduction. The synopsis emphasizes reducing health, social, and economic harms associated with substance use, and the structure of the bill prioritizes overdose prevention, disease screening, and access to care over punishment for users. No committee transcripts or votes were provided, so there is no recorded debate or roll-call history in the supplied materials.
The main point of contention likely centers on the balance between harm reduction and drug enforcement. Supporters would view the bill as a pragmatic, evidence-based response to overdose and infectious disease risks, while critics may object to the authorization of syringe and supply distribution, the immunity provisions, and the decriminalization of possession of paraphernalia for personal marijuana use. The bill preserves restrictions on trafficking, sales to minors, and paraphernalia tied to drug manufacturing or distribution, which suggests an attempt to draw a line between public health services and illegal drug commerce.
SB 249 would add a new Chapter 48 to Title 16 governing substance use harm reduction programs, giving the Division of Substance Abuse and Mental Health authority to license and regulate those programs and setting statewide standards for services, confidentiality, data practices, and immunity. It would also amend Delaware’s controlled substances/paraphernalia laws in Title 16 to narrow the paraphernalia definition, revise offenses and exemptions, and replace criminal treatment of personal-use marijuana paraphernalia with a civil penalty. In addition, it repeals Sections 7990 through 7996 of Title 29, removing related provisions from the state code and conforming existing law to the new framework.
The bill’s tone and structure indicate a generally supportive, public-health-focused sentiment. It is framed as an evidence-based harm reduction measure that seeks to reduce overdose deaths, disease transmission, and other harms associated with substance use while protecting participant dignity and confidentiality. Because no committee discussion or votes were provided, there is no documented legislative opposition or support in the supplied record beyond the bill’s own policy findings and synopsis.
The likely areas of contention are the bill’s authorization of harm reduction programs, including mobile and peer-delivered services, and the immunity protections for providers and staff. Opponents may also object to the requirement that programs distribute sterile supplies, drug-testing strips, and opioid antagonists, as well as the active encouragement of secondary supply distribution. Another likely flashpoint is the reclassification of possession of paraphernalia for personal marijuana use from a criminal offense to a civil penalty, while supporters would argue that the bill appropriately preserves criminal penalties for manufacture, sale, and delivery to minors.